What is the share price of Auro Laboratories Ltd (AUROLAB) today?
The share price of AUROLAB as on 18th July 2025 is ₹285.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Auro Laboratories Ltd (AUROLAB) share?
The past returns of Auro Laboratories Ltd (AUROLAB) share are- Past 1 week: 11.25%
- Past 1 month: 6.57%
- Past 3 months: 12.86%
- Past 6 months: 9.36%
- Past 1 year: 65.16%
- Past 3 years: 218.30%
- Past 5 years: 560.64%
What are the peers or stocks similar to Auro Laboratories Ltd (AUROLAB)?
The peers or stocks similar to Auro Laboratories Ltd (AUROLAB) include:What is the market cap of Auro Laboratories Ltd (AUROLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Auro Laboratories Ltd (AUROLAB) is ₹179.93 Cr as of 18th July 2025.What is the 52 week high and low of Auro Laboratories Ltd (AUROLAB) share?
The 52-week high of Auro Laboratories Ltd (AUROLAB) is ₹303 and the 52-week low is ₹156.40.What is the PE and PB ratio of Auro Laboratories Ltd (AUROLAB) stock?
The P/E (price-to-earnings) ratio of Auro Laboratories Ltd (AUROLAB) is 97.79. The P/B (price-to-book) ratio is 4.29.Which sector does Auro Laboratories Ltd (AUROLAB) belong to?
Auro Laboratories Ltd (AUROLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Auro Laboratories Ltd (AUROLAB) shares?
You can directly buy Auro Laboratories Ltd (AUROLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Auro Laboratories Ltd
AUROLAB Share Price
285.051.26% (-3.65)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AUROLAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AUROLAB Performance & Key Metrics
AUROLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 116.09 | 4.29 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.54 | 6.51 | 0.80% |
AUROLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AUROLAB Company Profile
Auro Laboratories Limited is engaged in the business of bulk drugs. It manufactures active pharmaceutical ingredients (APIs), intermediates and generic formulations.
SUNPHARMA
PE Ratio
37.40
37.40
1Y Return
6.85%
6.85%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.71
22.71
1Y Return
1.61%
1.61%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
62.06
62.06
1Y Return
14.59%
14.59%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
54.71
54.71
1Y Return
23.40%
23.40%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.59
18.59
1Y Return
5.28%
5.28%
Buy Reco %
48.39
48.39
AUROLAB Forecast
AUROLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
AUROLAB
AUROLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
AUROLAB Income Statement
AUROLAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 36.00 | 41.30 | 47.78 | 44.76 | 55.01 | 51.96 | 53.83 | 55.14 | 20.05 | 20.06 | ||||||||||
Raw Materials | 20.08 | 24.66 | 30.39 | 23.99 | 27.64 | 33.76 | 37.30 | 29.04 | 15.99 | 15.98 | ||||||||||
| Power & Fuel Cost | 1.29 | 1.48 | 1.64 | 1.69 | 1.60 | 1.67 | 2.08 | 2.43 | ||||||||||||
| Employee Cost | 2.72 | 2.80 | 2.87 | 3.48 | 3.64 | 3.70 | 3.76 | 3.91 | ||||||||||||
| Selling & Administrative Expenses | 2.52 | 3.27 | 4.18 | 5.03 | 5.84 | 5.86 | 4.73 | 7.31 | ||||||||||||
| Operating & Other expenses | 4.44 | 2.23 | 0.75 | 3.33 | 4.29 | 1.25 | 0.63 | 0.28 | ||||||||||||
EBITDA | 4.95 | 6.86 | 7.95 | 7.24 | 12.00 | 5.72 | 5.33 | 12.17 | 4.06 | 4.08 | ||||||||||
| Depreciation/Amortization | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.10 | 1.10 | ||||||||||
| PBIT | 4.09 | 5.93 | 6.94 | 6.22 | 10.96 | 4.70 | 4.26 | 11.08 | 2.96 | 2.98 | ||||||||||
| Interest & Other Items | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 1.08 | 1.08 | ||||||||||
| PBT | 2.91 | 4.72 | 6.07 | 5.64 | 10.50 | 3.87 | 3.45 | 10.34 | 1.88 | 1.90 | ||||||||||
| Taxes & Other Items | 2.11 | 1.19 | 1.67 | 1.58 | 3.32 | 1.03 | 1.00 | 2.55 | 0.04 | 0.35 | ||||||||||
| Net Income | 0.80 | 3.53 | 4.40 | 4.06 | 7.18 | 2.84 | 2.45 | 7.79 | 1.84 | 1.55 | ||||||||||
| EPS | 1.28 | 5.66 | 7.06 | 6.51 | 11.52 | 4.56 | 3.93 | 12.50 | 2.95 | 2.49 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
AUROLAB Company Updates
AUROLAB Stock Peers
AUROLAB Past Performance & Peer Comparison
AUROLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Auro Laboratories Ltd | 97.79 | 4.29 | — |
| Sun Pharmaceutical Industries Ltd | 37.40 | 5.64 | 0.94% |
| Cipla Ltd | 22.71 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 62.06 | 15.63 | 0.91% |
AUROLAB Stock Price Comparison
Compare AUROLAB with any stock or ETFCompare AUROLAB with any stock or ETF
AUROLAB
AUROLAB Holdings
AUROLAB Shareholdings
AUROLAB Promoter Holdings Trend
AUROLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AUROLAB Institutional Holdings Trend
AUROLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AUROLAB Shareholding Pattern
AUROLAB Shareholding Pattern
AUROLAB Shareholding History
AUROLAB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing AUROLAB stock
smallcases containing AUROLAB stock
Looks like this stock is not in any smallcase yet.
AUROLAB Events
AUROLAB Events
AUROLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AUROLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AUROLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AUROLAB has not given any dividends in last 5 years
AUROLAB Dividends
AUROLAB Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAUROLAB Stock News & Opinions
AUROLAB Stock News & Opinions
Articles & Videos
Earnings
Auro Laboratories standalone net profit declines 83.19% in the March 2025 quarter
Net profit of Auro Laboratories declined 83.19% to Rs 0.39 crore in the quarter ended March 2025 as against Rs 2.32 crore during the previous quarter ended March 2024. Sales declined 38.64% to Rs 7.40 crore in the quarter ended March 2025 as against Rs 12.06 crore during the previous quarter ended March 2024. For the full year,net profit declined 76.38% to Rs 1.84 crore in the year ended March 2025 as against Rs 7.79 crore during the previous year ended March 2024. Sales declined 63.83% to Rs 19.40 crore in the year ended March 2025 as against Rs 53.64 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales7.4012.06 -39 19.4053.64 -64 OPM %10.9519.98 -17.5319.89 - PBDT0.643.13 -80 2.9811.43 -74 PBT0.352.85 -88 1.8810.34 -82 NP0.392.32 -83 1.847.79 -76 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Auro Laboratories revises board meeting date
Auro Laboratories has revised the meeting of the Board of Directors which was scheduled to be held on 23 May 2025. The meeting will now be held on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Auro Laboratories announces board meeting date
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 23 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Auro Laboratories standalone net profit declines 98.17% in the December 2024 quarter
Net profit of Auro Laboratories declined 98.17% to Rs 0.05 crore in the quarter ended December 2024 as against Rs 2.73 crore during the previous quarter ended December 2023. Sales declined 83.04% to Rs 3.05 crore in the quarter ended December 2024 as against Rs 17.98 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3.0517.98 -83 OPM %14.7522.64 - PBDT0.344.05 -92 PBT0.073.78 -98 NP0.052.73 -98 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Auro Laboratories to hold board meeting
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Auro Laboratories standalone net profit declines 81.73% in the September 2024 quarter
Net profit of Auro Laboratories declined 81.73% to Rs 0.36 crore in the quarter ended September 2024 as against Rs 1.97 crore during the previous quarter ended September 2023. Sales declined 76.88% to Rs 3.10 crore in the quarter ended September 2024 as against Rs 13.41 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.1013.41 -77 OPM %23.2322.60 - PBDT0.753.00 -75 PBT0.482.73 -82 NP0.361.97 -82 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Auro Laboratories to hold board meeting
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Auro Laboratories standalone net profit rises 5.63% in the June 2024 quarter
Net profit of Auro Laboratories rose 5.63% to Rs 0.75 crore in the quarter ended June 2024 as against Rs 0.71 crore during the previous quarter ended June 2023. Sales declined 43.81% to Rs 5.72 crore in the quarter ended June 2024 as against Rs 10.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales5.7210.18 -44 OPM %23.0811.39 - PBDT1.271.25 2 PBT1.000.98 2 NP0.750.71 6 Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Auro Laboratories to announce Quarterly Result
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 9 August 2024Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -14.84%, vs industry avg of 10.15%
Over the last 5 years, market share decreased from 0.02% to 0%
Over the last 5 years, net income has grown at a yearly rate of -14.64%, vs industry avg of 20.04%